Rapid Diagnosis of XDR and Pre-XDR TB: A Systematic Review of Available Tools
Arch. bronconeumol. (Ed. impr.)
; 58(12): 809-820, dic. 2022. ilus, tab
Artigo
em Inglês
| IBECS
| ID: ibc-213185
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Introduction:
No previous systematic reviews have comprehensively investigated the features of Xpert MTB/XDR and other rapid tests to diagnose pre-XDR/XDR-TB. The aim of this systematic review is to assess existing rapid diagnostics for pre-XDR/XDR-TB from a point-of-care perspective and describe their technical characteristics (i.e., sensitivity, specificity, positive and negative predictive values).Methods:
Embase, PubMed, Scopus, and Web of Science were searched to detect the articles focused on the accuracy of commercially available rapid molecular diagnostic tests for XDR-TB according to PRISMA guidelines. The analysis compared the diagnostic techniques and approaches in terms of sensitivity, specificity, laboratory complexity, time to confirmed diagnosis.Results:
Of 1298 records identified, after valuating article titles and abstracts, 97 (7.5%) records underwent full-text evaluation and 38 records met the inclusion criteria. Two rapid World Health Organization (WHO)-endorsed tests are available Xpert MTB/XDR and GenoType MTBDRsl (VER1.0 and VER 2.0). Both tests had similar performance, slightly favouring Xpert, although only 2 studies were available (sensitivity 91.494; specificity 98.599; accuracy 97.297.7; PPV 88.999.1; NPV 95.898.9).Conclusions:
Xpert MTB/XDR could be suggested at near-point-of-care settings to be used primarily as a follow-on test for laboratory-confirmed TB, complementing existing rapid tests detecting at least rifampicin-resistance. Both Xpert MTB/XDR and GenoType MTBDRsl are presently diagnosing what WHO defined, in 2021, as pre-XDR-TB. (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Tuberculose Resistente a Múltiplos Medicamentos
/
Tuberculose Extensivamente Resistente a Medicamentos
/
Mycobacterium tuberculosis
Limite:
Humanos
Idioma:
Inglês
Revista:
Arch. bronconeumol. (Ed. impr.)
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
IRCCS/Italy
/
Kenyatta University/Kenya
/
Public Health Consulting Group/Switzerland
/
Universitary Hospital of Gran Canaria Dr. Negrin/Spain
/
University of Groningen/The Netherlands
/
University of Melbourne at the Peter Doherty Institute for Infection and Immunity/Australia
/
University of Sassari/Italy
/
University of Sydney/Australia